Stay updated with breaking news from Christoph koenen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
While other companies scrambled to implement clinical trial-related technology to deal with the pandemic, Otsuka was an early adopter of tools such. ....
MedCity News Otsuka launches pivotal trial of digital therapeutics for depression Otsuka Pharmaceutical is partnering with Click Therapeutics to launch a remote clinical trial to evaluate the effectiveness of digital therapeutics in reducing depressive symptoms. Shares0 Otsuka Pharmaceutical is launching a virtual study to see if digital therapeutics can reduce depression symptoms. It’s the next step in a partnership between the Tokyo-based drugmaker and Click Therapeutics, a digital health startup that is developing programs for smoking cessation, depression and insomnia. They plan to enroll up to 540 patients in a randomized, controlled trial that will test the digital therapeutic’s efficacy in patients that are taking antidepressants. The remote trial will be conducted using Verily’s Project Baseline platform. ....
Share Otsuka Pharmaceutical and Click Therapeutics have announced the launch of a new, fully remote clinical trial being conducted on Verily s Project Baseline platform. Called the Mirai study, it will be measuring a digital therapeutics intervention s effectiveness in reducing symptoms of depression among adults who have a major depressive disorder (MDD) diagnosis and are on antidepressant monotherapy. Christoph Koenen, EVP and chief medical officer of Ostuka Pharmaceutical Companies U.S., told MobiHealthNews that the pivotal, randomized, controlled trial will enroll as many as 540 patients across the country over 10 weeks of active participation. The study will be measuring safety and participants change from baseline on the Montgomery-Åsberg Depression Rating Scale, a standardized measure of depressive symptoms. ....
Freespira s digital therapeutic for PTSD, panic disorder, panic attacks and other panic symptoms. In addition to bringing the treatment to members living in Pennsylvania, Delaware and West Virginia, the agreement will also provide remote coaching on how to use Freespira to those not already receiving support from a behavioral health professional, according to the announcement. We are pleased with the clinical and financial outcomes achieved for our health plan members through the use of Freespira, Demetrios C. Marousis, director of behavioral health at Highmark, said in a statement. This breakthrough, drug-free treatment has reduced the impact of symptoms associated with panic attacks, resulting in reduced use of medications and other healthcare costs for symptom management. Freespira adds value to our members plans and helps us to create a remarkable health care experience, freeing people to be their best. ....
Share 23andMe s new COVID-19 resource. Consumer genomics company 23andMe has released a new interactive tool that allows users to see how various health factors could impact the risk of COVID-19 hospitalization. The COVID-19 Severity Calculator pulls data from the company s COVID-19 study, which included 10,000 participants diagnosed with the disease and 750 who were hospitalized. 23andMe warned that the tool shouldn t be used as a predictor for individual risk, and doesn t take lifestyle or certain underlying health conditions into account. However, it does identify certain characteristics that were frequently tied to severe symptoms and hospitalization, chief among which were obesity, Type 2 diabetes and lack of exercise. ....